Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perinatal group B streptococcal disease.

Paul T Heath1, Anne Schuchat

  • 1Vaccine Institute and Division of Child Health, St George's, University of London, London SW17 0RE, UK. pheath@sgul.ac.uk <pheath@sgul.ac.uk>

Best Practice & Research. Clinical Obstetrics & Gynaecology
|March 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal Group B <i>Streptococcus</i> Vaccination: A Three-Country European Consortium to Improve Surveillance and Data Readiness.

Clinical epidemiology·2026
Same author

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.

The Lancet. Infectious diseases·2026
Same author

Current knowledge and future perspectives on management and prevention of group B streptococcus in neonates and young infants.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Preterm infants: immunity and immunisation.

Archives of disease in childhood. Fetal and neonatal edition·2026
Same author

Methodological framework for the surveillance of healthcare-associated infections in high-risk infants: the NeoIPC surveillance core module protocol.

Antimicrobial resistance and infection control·2026
Same author

Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Group B Streptococcus (GBS) causes neonatal sepsis and meningitis. Early antibiotic administration before birth, guided by risk factors or swabs, is crucial for preventing GBS infections in newborns.

Area of Science:

  • Obstetrics and Gynecology
  • Neonatal Medicine
  • Infectious Diseases

Background:

  • Group B Streptococcus (GBS) is a primary cause of neonatal sepsis and meningitis.
  • Despite treatment, GBS infections lead to significant infant morbidity and mortality.
  • Effective prevention strategies are essential to reduce GBS-related adverse outcomes.

Purpose of the Study:

  • To review prevention strategies for neonatal Group B Streptococcus infections.
  • To highlight the importance of timely antibiotic administration in preventing early-onset GBS disease.
  • To compare risk-factor-based versus swab-based screening for GBS.

Main Methods:

  • Review of current obstetric and midwifery practices for GBS prevention.
  • Analysis of two primary GBS screening strategies: clinical risk factors and late-pregnancy vaginal/rectal swabs.

Related Experiment Videos

  • Discussion of the efficacy and implications of each prevention approach.

    • Main Results:

    • Antibiotic administration prior to delivery is key to preventing early-onset GBS disease.
    • Two main strategies exist for identifying at-risk pregnancies: clinical risk factors or GBS screening via swabs.
    • Swab-based screening demonstrates higher efficacy but may increase antibiotic exposure.

    Conclusions:

    • Prevention of neonatal GBS disease relies heavily on obstetricians and midwives.
    • The choice between risk-factor and swab-based strategies involves balancing efficacy with antibiotic stewardship.
    • Optimizing GBS prevention requires careful consideration of available screening methods.